Transdermal CBD Gel for DEE Seizure and Behavioral Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for developmental and epileptic encephalopathies, such as Lennox-Gastaut and Dravet Syndromes, fail to address behavioral problems effectively and often cause adverse side effects like somnolence and sedation, while oral CBD delivery is associated with gastrointestinal issues and psychoactive effects.
Innovation Solution
Transdermal administration of cannabidiol (CBD) to treat behavioral problems and seizures in subjects with developmental and epileptic encephalopathy, using a permeation-enhanced gel formulation to avoid first-pass metabolism and gastrointestinal adverse events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral CBD delivery is used to treat seizures and behavioral problems, then therapeutic efficacy is achieved, but gastrointestinal adverse events and psychoactive effects occur
Solution Approach 1:
The patent uses a transdermal delivery system as an intermediary between the CBD compound and the bloodstream, avoiding direct contact with the gastrointestinal tract. The gel formulation applied to the skin serves as a mediator that enables drug absorption through the dermal layer without involving the digestive system, thereby eliminating GI adverse events while maintaining therapeutic efficacy.
Solution Approach 2:
The patent replaces the oral (mechanical swallowing and digestive processing) administration route with a transdermal (physical absorption through skin) route. This substitution changes the delivery mechanism from gastrointestinal processing to cutaneous absorption, avoiding first-pass metabolism and gastric acid degradation while maintaining drug bioavailability.
2Reliability
If antiepileptic medications are used to treat seizures, then seizure control is achieved, but behavioral problems and cognitive deficits are not addressed
Solution Approach 1:
The patent employs CBD as a multi-functional therapeutic agent that simultaneously addresses multiple symptom domains. Clinical observations indicate that CBD treatment not only reduces seizure frequency but also improves behavioral problems, cognitive functions, and quality of life measures, making a single treatment modality effective across multiple clinical dimensions rather than requiring separate medications for each symptom cluster.
3Reliability
If oral CBD is administered at higher doses to improve behavioral symptoms, then therapeutic benefit increases, but somnolence and sedation worsen
Solution Approach 1:
The patent replaces oral administration with transdermal delivery to alter the pharmacokinetic profile of CBD. This route substitution enables more controlled and sustained release of the compound into the bloodstream, avoiding the sharp peak concentrations associated with oral dosing that lead to excessive sedation, while still achieving effective levels for behavioral symptom improvement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces the intensity and frequency of adverse events, improves behavioral symptoms, and significantly decreases seizure frequency, with responders achieving 44% to 58% median reductions in seizures over six months, and shows qualitative improvements in alertness, engagement, and cognitive functions.
Implementation Method 1
transdermally administering an effective amount of cannabidiol (CBD) to the subject
Data Source
AI summary
The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject.